Kiniksa Pharmaceuticals Raises 2026 Revenue Guidance Following Strong ARCALYST Sales
Kiniksa Pharmaceuticals (KNSA) reported strong third-quarter 2026 results, highlighted by a significant increase in its full-year revenue guidance to between $1.045 billion and $1.050 billion. The growth is primarily driven by the flagship drug ARCALYST, which saw year-over-year revenue climb 58% to $286 million as physician adoption expanded into earlier stages of disease progression. The company is leveraging AI-driven marketing campaigns to increase patient engagement and is focusing its R&D on pipeline candidates like KPL-387 and KPL-1161. These candidates aim to provide less frequent dosing schedules compared to existing therapies, potentially strengthening Kiniksa's competitive position. The company's profitable sales growth is enabling it to self-fund its research and development efforts.
Tickers: $KNSA
Topics: clinical pipeline drug sales earnings call pharmaceuticals revenue guidance
Read the full article at Motley Fool
Part of the story Equinix Reports Strong Q3 2026 Results and Raises Full-Year Guidance (49 articles)